science
informative
controversial
Novo Nordisk faces major setback after Alzheimer's trial failure
Nov 24, 2025, 1:00 AM60
(Update: Nov 24, 2025, 6:13 PM)
science
informative
controversial
Novo Nordisk faces major setback after Alzheimer's trial failure
- Novo Nordisk's Rybelsus failed to show efficacy in slowing cognitive decline in Alzheimer's patients during late-stage trials.
- The trial results involved 3,808 patients aged 55 to 85 and aimed for a 20% reduction in cognitive decline.
- The failure highlights the challenges facing Novo Nordisk as it encounters stiff competition in the Alzheimer's medication market.
Insights
News 6 6
Related reports
Opinions
Story
“
analysis trends insight economic market global market global analysis insight economic insight geopolitical trends policy market shift trends analysis strategic impact market insight data analysis geopolitical geopolitical strategic strategic geopolitical economic impact geopolitical trends data policy shift analysis strategic data insight geopolitical data policy insight economic shift insight trends market strategic policy insight impact market impact global insight geopolitical policy data trends shift global global strategic policy data global trends global insight global trends analysis policy strategic policy data analysis...
2026 All rights reserved
2026 All rights reserved